I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Human capital, a crucial determinant of economic growth, is recognized as the level of education and health in a population. The term "expected human capital" signifies the number of years an individual remains at their peak productivity at the workplace between the ages of 20 and 64. A recent survey ranked India 158 among 195 countries in terms of expected human capital and, unfortunately, the average Indian\'s peak productive period lasts only 7 years, which is less than half that of a Chinese worker (peak productive period = 20 years). Besides, India ranks below all other countries in the South Asian region in terms of functional health.\[[@ref1]\]

People Matters-Sanofi Pasteur conducted a study in 221 corporate institutions in India in 2019 to assess the challenges of workplace-wellness programs. The survey showed that the majority (62%) of organizations did not take any measures to tackle an outbreak of infectious diseases at the workplace.\[[@ref2]\] Furthermore, lack of employee awareness is one of the crucial factors that affect the success of a wellness program. A recent survey conducted in major corporate organizations in metro cities showed a lack of understanding of influenza vaccines among employees.\[[@ref3]\] Another survey revealed that only 45% of employees were aware of flu shots offered at the workplace, in contrast to 77% among employers (who had implemented such programs).\[[@ref4]\]

Work performance challenges related to modifiable health behaviors (e.g. inadequate/lack of physical activity, smoking, obesity, etc.) are highly prevalent, ultimately leading to a loss of productivity and, thereby, affecting the economic/financial status of the organization. All these modifiable health factors not only contribute to increased levels of sickness absence but also give rise to the phenomena called "absenteeism and presenteeism." Absenteeism refers to the count of days absent from work, whereas presenteeism refers to reduced productivity while at work.\[[@ref5]\] A survey has shown that acute diseases such as influenza, diarrhea, malaria, and dengue, followed by lifestyle diseases such as stroke, cardiovascular diseases, diabetes, and mental disorders are primary contributors to workplace absenteeism.\[[@ref6]\] Furthermore, insurance data for the financial years 2014--2017 for India showed that influenza and pneumonia had the highest average claim amount paid for these financial years.\[[@ref7]\] This draws our attention toward the increasing burden of vaccine-preventable diseases (VPDs) in adults in India. Moreover, VPDs have been found to be associated with significant morbidity and disability in India.\[[@ref8]\]

B[URDEN AND]{.smallcaps} I[MPACT OF]{.smallcaps} VPDS [IN]{.smallcaps} W[ORKING]{.smallcaps} P[OPULATION AND]{.smallcaps} R[OLE OF]{.smallcaps} A[DULT]{.smallcaps} I[MMUNIZATION]{.smallcaps} {#sec1-2}
==============================================================================================================================================================================================

In India, it is challenging to estimate the actual burden of various diseases due to the scarcity of systematic epidemiological data. Of note, the most common pneumococcal diseases, that is, meningitis and pneumonia, are associated with high morbidity and mortality rates.\[[@ref9]\]

[Table 1](#T1){ref-type="table"} shows the prevalence/incidence of VPDs in India.\[[@ref9][@ref10][@ref11][@ref12][@ref13][@ref14]\]

###### 

Prevalence/incidence of vaccine-preventable diseases (VPDs) in India\[[@ref9][@ref14]\]

  --------------------------------------------------------------------------------------------------------------------------------------
  Disease                 Incidence/Prevalence
  ----------------------- --------------------------------------------------------------------------------------------------------------
  Influenza               Between 2015 and 2019, 126,906 H1N1 cases and 7865 deaths were reported.\[[@ref10]\]

  Pneumococcal disease\   As per a recent study, out of 374 adult invasive pneumococcal disease (IPD) cases:\
   Pneumonia\             146 patients suffered from pneumonia (39%).\
   Meningitis\            91 patients had meningitis (24.3%).\
   Septicemia             69 patients suffered from pneumococcal septicemia (18.4%).\[[@ref9]\]

  Hepatitis               In a study, among 599,605 cases tested for hepatitis A, 44,663 cases were found to be positive.\[[@ref11]\]\
                          India has \>37 million HBV carriers.\[[@ref12]\]

  Measles and rubella     55,399 cases of measles and 1066 cases of rubella (all age groups)\[[@ref13]\]

  Typhoid                 120/100,000 population-years in adults older than 15 years\[[@ref14]\]
  --------------------------------------------------------------------------------------------------------------------------------------

VPDs: Vaccine-preventable diseases

Burden of VPDs in workplace {#sec2-1}
---------------------------

The burden of influenza in the workplace is reflected in terms of work absenteeism, reduced work effectiveness, and increased physician office visits and hospitalization. Research suggests that influenza-like infections are associated with significant mean annual attack rates of 5.3% in vaccinated and 26.2% in nonvaccinated working employees.\[[@ref15]\] Influenza causes almost a 50% mean reduction in the activity level/effectiveness at work.\[[@ref16]\] A study by Tsai *et al*. reported that the mean work-loss hours per influenza-like illnesses is 23.6 h, and the work-loss hours are even higher in cases of influenza-like illness episodes associated with hospitalization (47 h).\[[@ref17]\] Furthermore, exposure to workplace inhalational hazards substantially contributes to the development of multiple chronic respiratory diseases, including pneumonitis, causing an occupational burden of 19%.\[[@ref18]\] Welders and those exposed to metal fumes are known to be at an increased risk for pneumococcal pneumonia and invasive pneumococcal disease (IPD).\[[@ref19]\]

Burden of comorbidities with increasing age and their impact {#sec2-2}
------------------------------------------------------------

The proportion of the elderly population is rapidly increasing, and aging is frequently accompanied by different comorbidities, chronic diseases, and increased susceptibility to infectious diseases.\[[@ref20][@ref21]\] Influenza increases the risk of hospitalization and intensive care unit (ICU) admission by 3--6-fold and 4-fold, respectively, in diabetes patients.\[[@ref22][@ref23]\] Also, the risk of myocardial infarction is nearly six times higher within the 1^st^ week of laboratory-confirmed influenza diagnosis.\[[@ref24]\] The overall incidence rate per 100,000 population of adult pneumococcal disease is 8.8 in healthy adults, 51.4 in adults with diabetes, 62.9 in adults with chronic lung disease, and 93.7 in adults with chronic heart disease. The incidence rates are increased with advancing age in adults with comorbidities such as chronic lung disease, diabetes, etc.\[[@ref25]\] A study conducted among 173 immunocompetent elderly individuals with community-acquired pneumonia revealed that cardiopulmonary comorbidities account for 42% of pneumonia cases in this study population.\[[@ref26]\]

Challenges of adult immunization in India {#sec2-3}
-----------------------------------------

Adult immunization is a highly neglected and underpublicized issue. Even among published guidelines from international organizations such as the World Health Organization (WHO), there is a dearth of a consensus regarding the optimal strategy for adult immunization, and most importantly, the issue of adult immunization in developing countries remains unaddressed.\[[@ref27]\] Lack of awareness among the general population, failure of health care providers (HCPs) to monitor patients\' vaccination status, lack of specialized vaccination centers for adults, and lack of drive among policymakers to promote adult vaccination are key challenges to adult immunization in India.\[[@ref28][@ref29][@ref30]\]

Significance of adult vaccination and its benefits to an organization {#sec2-4}
---------------------------------------------------------------------

Adults require vaccination for numerous reasons. One of the primary reasons is age-related immunosenescence, which reduces an individual\'s resistance to infections.\[[@ref31][@ref32]\] Moreover, adults are frequently associated with chronic illnesses that increase susceptibility to infections.\[[@ref31][@ref32]\] Interestingly, the proportion of adults who die of VPDs each year is 350-fold higher vs the corresponding figure for children.\[[@ref32]\] The inability of childhood vaccination to offer long-term benefits, as well as the changing disease epidemiology with the emergence and reemergence of certain diseases (tuberculosis, malaria), is why adult vaccination is important.\[[@ref8][@ref31][@ref32]\]

Outcomes of adult vaccinations to organizations {#sec2-5}
-----------------------------------------------

Workplace vaccination has several benefits for employers as well as employees. Workplace vaccination leads to reduced sick leaves and doctor visits and improved health and morale among employees. This reduces absenteeism, improves work productivity, and translates to financial benefits for the employer.\[[@ref33][@ref34]\] For instance, influenza vaccination was associated with a 23% reduction in the absence rate and a 30% improvement in lost working days and related expenses. This also led to a cost-benefit ratio of 4.2, that is, a return of €4 at the cost of €1 due to curtailed absenteeism.\[[@ref35]\] The economic benefits of polysaccharide 23-valent (PPSV23) and/or conjugate pneumococcal vaccine 13-valent (PCV13) in adults, the elderly, and at-risk groups have been evaluated in many studies.\[[@ref36][@ref37]\] A sequential pneumococcal vaccination with PCV13 first, followed by unconjugated PPSV23, was associated with potential savings of €115--€187 million for medical and nonmedical costs due to a substantial reduction in total IPD cases, as well as hospitalized all-cause nonbacteremic pneumonia (NBP) and outpatient NBP cases.\[[@ref36]\] A Spanish dynamic transmission model reported that the use of PCV13 for 5 years in a cohort of patients aged 65--69 years would avoid 10,360 cases of pneumococcal disease and 699 deaths, leading to an increase of 14,736 life-years. This may result in a corresponding cumulative saving of €3.8 million at a fixed price (€4.9 million at current prices) and would be an efficient intervention for the Spanish National Health System.\[[@ref37]\]

A highly important aspect of workplace adult vaccination is to extend the benefits/provision of adult vaccination to the family members of employees. Considering the highly contagious nature of the VPDs such as influenza, varicella, and pneumococcal infections (caused by Streptococcus pneumoniae), extending vaccination benefits to family members may reduce the rate of absenteeism among employees, owing to self-infection or family obligation.\[[@ref38][@ref39][@ref40]\]

Role of vaccination in reducing comorbidities {#sec2-6}
---------------------------------------------

Influenza and pneumococcal vaccines have beneficial effects beyond the direct advantages of vaccines. Influenza vaccines have been reported to reduce the risk of heart attack by 19%--45%, which is equipotent or better than preventive treatments such as cholesterol-lowering drugs (reduce risk 25--30%) and lifestyle changes such as quitting smoking (reduces risk by 32--43%).\[[@ref41]\] The risk of all-cause mortality is 31% lower in influenza-vaccinated individuals with heart failure as compared with nonvaccinated patients.\[[@ref42]\] A meta-analysis has shown that influenza vaccines have a protective effect against major adverse cardiovascular disease events.\[[@ref43]\] Influenza vaccination also helps in reducing hospitalization by 54% in elderly patients with diabetes.\[[@ref44]\]

On the other hand, pneumococcal vaccines are known to reduce the risk of comorbidities. In a meta-analysis of eight observational studies, pneumococcal vaccination was associated with a significant reduction in the risk of the acute coronary syndrome in the older population (≥65 years old).\[[@ref45]\] Vaccination with PCV13 induces antibody responses to vaccine serotypes in patients (≥50 years old) with end-stage renal disease and on dialysis at 2 months postvaccination.\[[@ref46]\] In diabetes patients, pneumococcal vaccination confers a significant reduction in morbidity and mortality related to pneumococcal disease.\[[@ref47]\] The Research Society for the Study of Diabetes in India (RSSDI) 2018 recommends patient education on pneumococcal and influenza vaccine to all adult diabetes patients. The recommendation is to use PCV13 for adults ≥50 years followed by a dose of PPSV23 at least 1 year later (and at least 5 years after their previous PPSV23 dose), depending on the clinical judgment of the physician.\[[@ref48]\] Pneumococcal vaccination also decreases the risk of myocardial infarction and cerebrovascular events in the elderly.\[[@ref49]\] The conjugated pneumococcal vaccine has shown promising effects in terms of reducing the rate of antibiotic resistance by slowing the spread of resistant pneumococcal serotypes (19A) and also by averting disease occurrence. Therefore, the use of antibiotics can be avoided.\[[@ref50]\] Dual vaccination with the pneumococcal and influenza vaccines is effective in protecting elderly people with chronic illness from developing complications associated with respiratory, cardiovascular, and cerebrovascular diseases---thereby reducing hospitalization, coronary or intensive care admissions, and death.\[[@ref51]\]

Adult vaccination plays an important role in reducing the burden of VPDs, as well as in reducing workplace absenteeism, thus, improving productivity. Ultimately, it contributes to greater profits for the organization.\[[@ref6]\] Considering the necessity for increased awareness regarding the often-underestimated concept of adult vaccination in India, an expert meeting was held on 1 December 2019 under the aegis of the Indian Association of Occupational Health (IAOH) with the purpose of drawing attention to these issues and working toward developing guidelines on adult vaccination in occupational health settings. The scientific deliberations led to the formulation of consensus recommendations on adult vaccination in the context of occupational health settings in India.

A[DULT]{.smallcaps} V[ACCINATION:]{.smallcaps} C[URRENT]{.smallcaps} G[UIDELINES IN]{.smallcaps} I[NDIA AND]{.smallcaps} D[IFFERENT]{.smallcaps} R[ECOMMENDATIONS]{.smallcaps} {#sec1-3}
==============================================================================================================================================================================

Unlike the Pediatrics Immunization Guidelines, several divergences exist from region to region regarding adult vaccination in India. The most popular guidelines in India for adult vaccination are the WHO guidelines, guidelines of the Geriatric Society of India, the Advisory Committee on Immunization Practices (ACIP) guidelines from the Centers for Disease Control and Prevention (CDC), Association of Physicians of India---Expert panel guidelines, Research Society for Study of Diabetes in India guidelines, Indian Society of Nephrology guidelines, and Indian Medical Association (IMA) guidelines.\[[@ref30][@ref52][@ref53]\]

The recommended vaccines for all healthy adults in India are as follows:\[[@ref53][@ref54]\]

Influenza (\>19 years onwards)Pneumococcal (\>50 years)Pneumococcal conjugate vaccine 13-valentPneumococcal polysaccharide vaccine 23-valentHuman papillomavirus (15--45 years)Herpes zoster (\>60 years)DPT (diphtheria, pertussis, and tetanus) (19 years onwards)MMR (measles, mumps, and rubella) (19--60 years old).

Pneumococcal disease: Burden, serogroups, and available vaccines {#sec2-7}
----------------------------------------------------------------

Asia is highly burdened with pneumonia patients, with India being the highest contributor with 43 million cases.\[[@ref55]\] In India, pneumonia and meningitis are the most common IPDs.\[[@ref56]\] Pneumonia accounts for 39% of the total IPD cases.\[[@ref9]\] Pneumococcal infection is associated with an increased risk of hospitalization due to heart diseases, as well as high in-hospital mortality.\[[@ref57]\] In India, IPD is associated with the highest case-fatality rate (28%) among adults aged \>50 years.\[[@ref29]\] According to the 2017 Global Burden of Disease study, the reported incidence and mortality of pneumococcal infection increased by 26% and 33% among the 50--69 years and \>70 years age groups, respectively.\[[@ref58]\] The most common serotypes isolated in India are 1, 3, 5, 19F, 8, 14, 23F, 4, 19A, and 6B. These serotypes account for 54.9% of IPD cases. A high nonsusceptibility to co-trimoxazole and the slow emergence of resistance to penicillin, tetracycline, and erythromycin has been reported. Vaccines are advocated by various Indian health care bodies/groups for older and younger adults with certain medical conditions.\[[@ref56]\]

There are two types of pneumococcal vaccine: unconjugated capsular polysaccharide antigens (PPSV 23) and capsular polysaccharides conjugated with a protein carrier (PCV13). [Table 2](#T2){ref-type="table"} highlights the detailed characteristics of both vaccines.\[[@ref50][@ref59][@ref60][@ref61]\]

###### 

Characteristics for pneumococcal vaccines\[[@ref50][@ref59][@ref61]\]

  Characteristics                                                                                                                                    PPSV23                                                                                                                                    PCV13
  -------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------
  Type of vaccine                                                                                                                                    Unconjugated capsular polysaccharide antigens                                                                                             Capsular polysaccharides conjugated with a protein carrier
  Contains antigens from 23 common serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F)   Contains antigens from 13 common serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F)                                       
  Immune response                                                                                                                                    T-cell-independent immune response (IgM antibody produced, response declines in 3-5 years, and no anamnestic response at revaccination)   T-cell-dependent immune response (larger duration and boosting effect at revaccination)
  Efficacy                                                                                                                                           Considerable efficacy proven against IPD (50-70%) in immunocompetent elderly individuals                                                  High efficacy (80%-90%) against vaccine-type IPD proven in children
  Unclear (null to small) efficacy against nonbacteremic pneumococcal pneumonia                                                                      At present, relatively small serotype coverage for IPD in the elderly (30-40%)                                                            
  No efficacy demonstrated in reducing nasopharyngeal carriage                                                                                       Potential efficacy in reducing nasopharyngeal carriage                                                                                    
  No impact proved in reducing overall pneumococcal disease burden                                                                                   Future reduction of vaccination impact in adults/elderly (because of indirect effects from pediatric use of PCV13)                        

IPD: invasive pneumococcal disease; IgM: immunoglobulin M; PPSV23: 23-valent pneumococcal polysaccharide vaccine; PCV13: 13-valent pneumococcal conjugate vaccine

Studies reveal that the initial PCV13 dose has the potential to enhance responses to a subsequent PPSV23 dose, compared with PCV13 alone.\[[@ref62]\] Pneumococcal conjugate vaccine 13 displays a more robust or greater immune response compared to PPSV23 in the majority of shared pneumococcal serotypes.\[[@ref56]\]

Based on the serotype covered by the conjugated form, that is, PCV13, and considering the seroprevalence in India, it is crucial to add PCV13 to ensure coverage for all prevalent serotypes in the country.\[[@ref56]\] Different professional societies in India, such as the Geriatric Society, the Indian Society of Nephrology, the Association of Physicians of India, the RSSDI, IMA, and Mass Gathering Advisory Board Consensus Recommendation 2016, have recommended the implementation of pneumococcal vaccination in adults.\[[@ref48][@ref52][@ref53][@ref59][@ref63][@ref64]\]

Various guidelines have advocated the use of pneumococcal vaccines sequentially for preventing disease occurrence among older adults. The chronological evolution of pneumococcal vaccine recommendations from global advocacy groups is detailed in [Table 3](#T3){ref-type="table"}.\[[@ref65][@ref66]\]

###### 

Chronological evolution of pneumococcal vaccine recommendations\[[@ref65][@ref66]\]

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Advocacy group/body                                                               Recommendation/s
  --------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Global Initiative for Chronic Obstructive Lung Disease (GOLD, 2019)\[[@ref65]\]   PCV13 and PPSV23 recommended for all patients ≥65 years of age.\
                                                                                    PPSV23 also recommended for younger COPD patients with significant comorbid conditions, including chronic heart or lung disease.

  Advisory Committee on Immunization Practices (ACIP, 2019)\[[@ref66]\]             ACIP recommends administration of PCV13 based on shared clinical decision-making for adults aged ≥65 years (who do not have an immunocompromising condition \[e.g., CSF leak, or cochlear implant\] and who have not previously received PCV13).\
                                                                                    If the decision is made to administer PCV13, it should be given at least 1 year before PPSV23. PCV13 and PPSV23 should not be co-administered.\
                                                                                    ACIP continues to recommend PCV13 in series with PPSV23 for adults aged ≥19 years with an immunocompromising condition, CSF leak, or cochlear implant.
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

COPD: chronic obstructive lung disease; PPSV23: 23-valent pneumococcal polysaccharide vaccine; PCV13: 13-valent pneumococcal conjugate vaccine; CSF: cerebrospinal fluid

Influenza: Burden and available vaccines {#sec2-8}
----------------------------------------

Influenza viruses are highly unstable in nature and cause pandemics. [Figure 1](#F1){ref-type="fig"} highlights the year-wise prevalence of influenza and mortality due to influenza. In 2017, the virus was unusually widespread in various parts of the country and caused three times higher mortality than in the pandemic year, that is, 2009.\[[@ref10]\]

![Number of reported cases and deaths due to influenza.\[[@ref10]\]](IJOEM-24-3-g001){#F1}

The following prefilled syringes of influenza vaccines are available in India:\[[@ref53]\]

Trivalent inactivated vaccineQuadrivalent inactivatedLive, attenuated nasal spray (lyophilized)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Vaccines for influenza in adults: Recommendations
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  One dose every year is recommended.\
  For inactivated vaccines, 0.5 mL is administered intramuscularly in the deltoid.\
  Live, attenuated vaccine is sprayed into each nostril.\[[@ref53]\]\
  The trivalent vaccine provides protection against two strains of influenza A virus and one strain of influenza B strain, whereas the quadrivalent vaccine provides protection against one additional influenza B strain.\[[@ref67]\]\
  The quadrivalent vaccine is recommended for yearly administration.\[[@ref68]\]

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A number of studies have shown the beneficial effects and safety of concomitant use of pneumococcal and influenza vaccines \[[Table 4](#T4){ref-type="table"}\].\[[@ref69][@ref70]\] Therefore, PCV13 and influenza vaccine (trivalent/quadrivalent) can be recommended concomitantly.

###### 

Concomitant use of pneumococcal and influenza vaccines\[[@ref69][@ref70]\]

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study authors                      Patients                                                                                                                                                                                                      Outcome of co-administration of pneumococcal and influenza vaccines
  ---------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------
  Sumitani *et al*.\[[@ref69]\]      A total of 98 adults with chronic respiratory disease underwent the additive inoculation of influenza vaccine (I-V) and 23-valent pneumococcal vaccine (P-V) to prevent lower respiratory tract infections.   Significant reduction in:\
                                                                                                                                                                                                                                                    Number of respiratory infections (3.16 vs 1.95 infections; *P*=0.0004)\
                                                                                                                                                                                                                                                    Number of hospitalizations (0.79 vs. 0.43 hospitalizations; *P*=0.001)

  Christenson *et al*.\[[@ref70]\]   100,242 participants aged ≥65 years; 76% of the participants received both vaccines.                                                                                                                          The incidence of hospital treatment was lower in the vaccinated group vs non-vaccinated group.\
                                                                                                                                                                                                                                                   In the vaccinated group, the incidence of hospital treatment was:\
                                                                                                                                                                                                                                                    46% lower for influenza\
                                                                                                                                                                                                                                                    29% lower for pneumonia\
                                                                                                                                                                                                                                                    36% lower for pneumococcal pneumonia\
                                                                                                                                                                                                                                                    52% for IPD\
                                                                                                                                                                                                                                                   57% lower mortality was observed in the vaccinated cohort (15.1 vs 34.7 deaths per 1000 inhabitants).
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IPD: Invasive pneumococcal disease

Hepatitis A and B: Burden and available vaccines {#sec2-9}
------------------------------------------------

Viral hepatitis is a major healthcare problem in India. The health threat posed by hepatitis is comparable to three dreadful CDs---HIV/AIDS, malaria, and tuberculosis.

Hepatitis A virus (HAV) is accountable for 10--30% of acute hepatitis and 5--15% of acute liver failure cases.\[[@ref71]\] The prevalence of hepatitis B is estimated to be 2--7% based on the presence of surface antigen.\[[@ref72][@ref73]\] India has around 50 million hepatitis B virus (HBV) carriers.\[[@ref73]\] Chronic HBV infections are responsible for 40--50% of hepatocellular carcinoma and 20--30% of cases of cirrhosis.\[[@ref72]\]

Vaccines available for immunization against HAV include inactivated vaccines such as single-antigen (HAV antigen) vaccines or combination vaccines containing both HAV and HBV antigens. For hepatitis B, recombinant DNA, inactivated subunit vaccine is available.\[[@ref53]\]

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Vaccines for hepatitis A and B in adults: Recommendations
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Single-antigen vaccine formulations should be administered in a two-dose schedule at 0 and 6-12 months.\[[@ref53]\]\
  If the combined hepatitis A and hepatitis B vaccine is used, administer three doses at 0, 1, and 6 months; alternatively, a four-dose schedule, administered on days 0, 7, and 21 to 30 followed by a booster dose at month 12 may be used.\[[@ref74]\]

  Hepatitis A immunization is recommended for the following groups of adults:\[[@ref64]\]\
  People with chronic liver disease\
  Men who have sex with men\
  People who use illegal drugs\
  People infected with other hepatitis viruses\
  People who receive clotting factor concentrates\
  People who have received or are awaiting a liver transplant\
  Food-handlers

  Live HBV is administered subcutaneously at a dose of 0.5 mL.\
  For hepatitis B, recombinant DNA or plasma-derived, inactivated subunit vaccine is available.\
  For adult hepatitis B vaccination, a three-dose series is recommended to those people not previously vaccinated.\
  The second dose should be administered one month after the first dose; the third dose should be administered at least 6 months after the first dose.\
  The recommended dose at \>18 years of age is 1 mL (20 µg) given intramuscularly.\[[@ref53]\]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Measles, mumps, rubella (MMR): Burden and available vaccines {#sec2-10}
------------------------------------------------------------

According to the WHO global report, there were 55,399 cases of measles and 1,066 cases of rubella in India in 2018.\[[@ref13]\] Mumps outbreaks occur more in densely populated places such as hostels, colleges, schools, military barracks, and poor socioeconomic settings. In a sailor training center in India, a total of 58 cases of mumps were reported in 3 months.\[[@ref75]\] A recent study conducted by health science students at Manipal University, India found the prevalence of serological susceptibility to rubella to be 16.6%.\[[@ref76]\]

  --------------------------------------------------------------------------------------------------------------------------------
  Vaccines for MMR in adults: Recommendations
  --------------------------------------------------------------------------------------------------------------------------------
  For MMR, live, attenuated vaccine is available.\
  All adults should receive two doses of MMR vaccine at 4-8-week intervals. If previously immunized, only one dose is required.\
  The dosage for the MMR vaccine is 0.5 mL by the subcutaneous route in the upper arm.\[[@ref53]\]

  --------------------------------------------------------------------------------------------------------------------------------

The available vaccines in India are listed below:\[[@ref53]\]

Measles only (M).Combination of:Measles and rubella (MR)Measles, mumps, and rubella (MMR)Measles, mumps, rubella, and varicella (MMRV).

Diphtheria, pertussis, and tetanus (DPT): Burden and available vaccines {#sec2-11}
-----------------------------------------------------------------------

Globally, the rising incidence of diphtheria in adults is a point of concern, with around 600,000 cases reported annually.\[[@ref77]\] Data on the incidence of adult pertussis in India are scarce but the incidence of adult pertussis is assumed to be high in states where childhood immunization coverage is adequate because the reduced natural circulation of pertussis leads to infrequent adolescent boosting.\[[@ref78]\] Tetanus poses a public health problem in several parts of the world, especially in tropical developing countries. In 2008, tetanus caused more than 61,000 deaths worldwide.\[[@ref77]\]

The available DPT vaccines in India are listed below:\[[@ref53]\]

DTwP: Diphtheria, tetanus, and whole-cell pertussis vaccine, commonly known as a triple antigen.DTaP: Diphtheria, tetanus, and acellular pertussis vaccine.Tdap: Diphtheria, tetanus, and acellular pertussis vaccine (reduced antigen content).DT: Diphtheria and tetanus vaccine.Td: Diphtheria (reduced dose) and tetanus vaccine.

  ---------------------------------------------------------------------------------------------------------------------------------------------------
  Vaccines for DPT in adults: Recommendations
  ---------------------------------------------------------------------------------------------------------------------------------------------------
  The two types of DPT vaccine are whole-cell pertussis vaccine and acellular pertussis vaccine.\[[@ref53]\]\
  People who previously did not receive Tdap at or after age 11 years should receive one dose of Tdap, then Td booster every 10 years.\[[@ref54]\]\
  Adults who have completed their primary vaccination during childhood should receive a Td vaccine every 10 years.\[[@ref53][@ref54]\]\
  The recommended dose is 0.5 mL administered intramuscularly at the anterolateral thigh or deltoid muscle.\[[@ref53]\]

  ---------------------------------------------------------------------------------------------------------------------------------------------------

DPT: Diphtheria, pertussis, and tetanus toxoids; Tdap: Tetanus, diphtheria, and pertussis; Td: Tetanus and diphtheria

Varicella (Chickenpox): Burden and available vaccines {#sec2-12}
-----------------------------------------------------

In India, \>30% of individuals aged 15 years or above are susceptible to varicella-zoster virus (VZV) infection, and the seroprevalence of VZV increases with age. In older individuals, varicella is more severe and prolonged with mortality rates being 15--25 times higher than in children.\[[@ref79]\] Recently, an outbreak of 110 cases of varicella was reported at a large private university in Chennai.\[[@ref80]\]

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Vaccines for varicella in adults: Recommendations
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Varicella vaccine is available as a live, attenuated vaccine.\[[@ref53]\]\
  A two-dose series at 4-8-week intervals if previously did not receive the varicella-containing vaccine (varicella or MMRV \[measles, mumps-rubella-varicella vaccine\] for children).\
  If previously received one dose of varicella-containing vaccine: One dose at least 4 weeks after the first dose.\[[@ref54]\]\
  The minimum interval between the first and the second doses should be 4 weeks, and 0.5 mL should be administered subcutaneously in the anterolateral thigh or upper arm.\[[@ref54]\]

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Typhoid: Burden and available vaccines {#sec2-13}
--------------------------------------

In India, the incidence of typhoid is 120/100,000 population-years in adults older than 15 years.\[[@ref14]\] Increasing antibiotic resistance and widespread multidrug-resistant strains make the treatment of typhoid difficult and challenging.\[[@ref81]\]

The typhoid vaccines available in India are listed below:

Vi-capsular polysaccharide vaccineVi-polysaccharide conjugate vaccine conjugated with tetanus toxoid (TCV)

  ----------------------------------------------------------------------------------------------------
  Vaccines for typhoid in adults: Recommendations
  ----------------------------------------------------------------------------------------------------
  The Vi vaccine is given as a single intramuscular dose of 0.5 mL.\
  In the case of the unconjugated vaccine, a booster is recommended once every 3 years.\[[@ref53]\]\
  Typhoid vaccination should compulsorily be given to food-handlers.\[[@ref82]\]

  ----------------------------------------------------------------------------------------------------

Rabies: Burden and available vaccines {#sec2-14}
-------------------------------------

Rabies is almost always fatal but preventable. One-third of global human deaths due to rabies in all age groups occur in India.\[[@ref83]\] A study reported the annual incidence of human rabies in India as 20,565 with the majority of patients being adult males.\[[@ref84]\]

In India, the following rabies vaccines are available:

Human diploid cell vaccine (HDCV)Purified chick embryo cell vaccine (PCEC)Purified duck embryo vaccine (PDEV)Purified Vero-cell rabies vaccine (PVRV)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Vaccines for rabies in adults: Recommendations
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  The rabies vaccine is available as a concentrated, purified cell culture, and as an embryonated egg-based vaccine.\
  Pre-exposure prophylaxis is particularly important for animal-handlers, veterinarians, and others employed in the care of animals (farmworkers, zookeepers). The regimen is one dose of 0.1 mL vaccine given intradermally on days 0, 7, and 21 or 28.\
  The schedule for postexposure prophylaxis is four doses at 0, 3, 7, and 14/28 days. For pre-exposure prophylaxis, three doses at 0, 7, and 28 days are recommended.\
  The usual dose is 1 mL given intramuscularly in anterolateral thigh or deltoid for human diploid cell vaccine, purified chick embryo cell vaccine, and purified duck embryo vaccine. It should never be given in the gluteal region. Purified Vero-cell vaccine should be given at 0.5 mL intramuscularly.\[[@ref53]\]

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Human papillomavirus (HPV): Burden and available vaccines {#sec2-15}
---------------------------------------------------------

More than 80% of sexually active women acquire genital human papillomavirus (HPV) by 50 years of age. About 6.6% of women are estimated to harbor cervical HPV infection. HPV serotypes 16 and 18 are responsible for nearly 76.7% of cervical cancer cases in India.\[[@ref85]\]

Two HPV vaccines (bivalent and quadrivalent vaccines) are commercially available. Bivalent vaccine (HPV2) protects against HPV types 16 and 18, whereas the quadrivalent one (HPV4) protects against four types of HPV (6, 11, 16, and 18).\[[@ref53]\]

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Vaccines for HPV in adults: Recommendations
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Vaccine for HPV is available as a recombinant protein capsid liquid vaccine.\
  A three-dose schedule (at 0, 1-2 months, and 6 months) is recommended for individuals aged 15-45 years.\
  The quadrivalent vaccine is administered at 0, 2, and 6 months, and the bivalent vaccine is administered at 0, 1, and 6 months. A usual dose of 0.5 mL is administered intramuscularly in the deltoid muscle of the upper arm.\[[@ref53]\]

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Vaccination schedule for health care workers: Recommendations {#sec2-16}
-------------------------------------------------------------

Ensuring health and safety in the work environment is of paramount importance. The adoption of safe working practices together with immunization will significantly improve the protection of the individual worker against specific VPDs.\[[@ref53]\] The ACIP strongly recommends that all health care workers should be vaccinated against (or have documented immunity to) hepatitis B, influenza, MMR, and varicella \[[Table 5](#T5){ref-type="table"}\].\[[@ref53][@ref86]\]

###### 

Vaccination schedule for healthcare workers\[[@ref53][@ref86]\]

  ---------------------------------------------------------------------------------------------------------
  Vaccine                  Dose/s   Schedule
  ------------------------ -------- -----------------------------------------------------------------------
  Hepatitis B              3        0-1-6 months

  Hepatitis A              2/1      0-6 months or single dose (live vaccine)

  Tdap                     1        1 dose every 10 years

  Varicella (Chickenpox)   2\*      2 doses at 4-8 weeks interval

  Polio (IPV)              1 or 2   If previously unimmunized, 2 doses (0, 4-8 weeks)

  Influenza                1        1 dose every year

  Pneumococcal\            12       \>50 years 1 single dose\
   PCV13\                           2 doses 5 years apart in high-risk patients
   PPSV23                           

  Typhoid                  1        Single dose. If unconjugated vaccine, give 3 yearly.

  MMR                      2        2 doses at 4-8 weeks interval

  Meningococcal (ACWY)     1        1 dose is enough; repeat dose after 3-5 years if still at risk

  Rabies                   3        Pre-exposure prophylaxis 0, 7, and 28 days (especially veterinarians)
  ---------------------------------------------------------------------------------------------------------

IPV: inactivated polio vaccine, Tdap: tetanus diphtheria (acellular) pertussis; MMR: measles, mumps, and rubella. \*Single dose for live vaccine

Vaccination schedule during pregnancy: Recommendations {#sec2-17}
------------------------------------------------------

[Table 6](#T6){ref-type="table"} provides recommendations for various vaccines during preconception and pregnancy.\[[@ref53]\]

###### 

Vaccination schedule during preconception and pregnancy\[[@ref53]\]

  Vaccine                                                                               Dose/s   Schedule                                                            Remarks
  ------------------------------------------------------------------------------------- -------- ------------------------------------------------------------------- ----------------------------------------------------------------------
  Hepatitis B                                                                           3        0-1-6 month                                                         Avoid conception for at least 4 weeks after MMR or varicella vaccine
  Varicella (Chickenpox)                                                                2        2 doses at 4-8 weeks                                                
  MMR                                                                                   2        2 doses at 4-8 weeks                                                
  HPV                                                                                   3        0-1 month (HPV2) or 2-6 months (HPV4)                               
  Influenza                                                                             1        1 dose every year                                                   
  During pregnancy                                                                                                                                                   
  TT/Td                                                                                 2        1 dose early in pregnancy and 2^nd^ dose 4 weeks after 1^st^ dose   
  Tdap                                                                                  1        3^rd^ trimester                                                     
  Influenza                                                                             1        1 at any stage of gestation                                         
  During lactation                                                                                                                                                   
  All vaccines except typhoid and yellow fever can be given as catch-up immunization.                                                                                

TT: tetanus toxoid; Td: tetanus and adult diphtheria; HPV: human papillomavirus; MMR: measles, mumps, and rubella

Vaccination for travel and mass gatherings: Recommendations {#sec2-18}
-----------------------------------------------------------

Several factors such as place of travel, staying conditions, and activities at the place of the visit are to be considered while choosing immunization for travelers. Hajj is one of the largest annual mass gatherings in the world.\[[@ref59]\] Meningococcal vaccine is compulsory for Hajj pilgrims.\[[@ref53]\] A high prevalence of respiratory tract infections (RTIs), including pneumonia, is evident in Hajj pilgrims.\[[@ref59]\] With Hajj pilgrims being highly susceptible to RTIs due to factors such as age, previous illnesses, intense crowding, and air pollution, the Preventive Vaccination for Pneumococcal Disease in Mass Gatherings (PREVENT) experts in Saudi Arabia advise the administration of the pneumococcal vaccine.\[[@ref87]\] [Tables 7](#T7){ref-type="table"} present vaccination recommendations for Hajj pilgrims and Kumbh Mela attendees.\[[@ref53][@ref87]\]

###### 

Vaccine recommendations for Hajj pilgrims and Kumbh Mela attendees\[[@ref53][@ref87]\]

  Vaccine recommendations             Comments
  ----------------------------------- --------------------------------------------------------------------------------------------------
  Hajj pilgrims\[[@ref53][@ref87]\]   
   Meningococcal                      Mandatory
   Influenza                          Recommended
   Polio (IPV)                        \<15 years, endemic countries
   Yellow fever                       Endemic countries
   Pneumococcal                       PCV13: 4 weeks before traveling for HajjPPSV23: Post-return from Hajj (depends upon risk status)
   Hepatitis A                        Recommended
   Hepatitis B                        Recommended
  Kumbh Mela attendees\[[@ref53]\]    
   Typhoid                            Strong recommendation
   Hepatitis A                        Strong recommendation
   Hepatitis B                        For prolonged stay
   Japanese encephalitis              If stay is over 1 month
   Influenza                          Strong recommendation
   Yellow fever                       Travelers coming from endemic countries
   Diphtheria, pertussis, tetanus     Should be up to date
   Measles, mumps, rubella            Should be up to date
   Rabies                             Pre-exposure prophylaxis
   Polio (IPV)                        1 booster (IPV)

IPV: inactivated polio vaccine; PCV 13: pneumococcal conjugate vaccine 13; PPSV23: 23-valent pneumococcal polysaccharide vaccine

V[ACCINATION]{.smallcaps} P[ROGRAM AT]{.smallcaps} W[ORKPLACE]{.smallcaps} {#sec1-4}
==========================================================================

In India, there are no guidelines or practices for vaccination in the workplace. A vaccination program at the workplace must ideally involve managers and supervisors. For a vaccination program at the workplace, the following points are to be considered:\[[@ref33]\]

It is very important to have clear objectives for the vaccination program.Subsequently, an execution team needs to be formed. The leadership team must be involved.A strong communication plan needs to be developed, focusing on how vaccination, as a wellness program, benefits employees.To create awareness about vaccination at the workplace, an organization must design employee-centric ways of communication, such as:Displaying posters in break rooms, cafeterias, and other high-visibility areas with the date and time details of the programCirculation of different article communications (e.g. e-mailers, intranet, newsletters, etc.)Business leaders may take initiatives in communicating the importance of vaccines to employees, to encourage mass participation.Social media may be engaged in creating awareness.A comfortable and convenient location and time for vaccination may ensure better participation.

A vaccination program at the workplace must ideally involve managers and supervisors. The leadership team must be involved. A comfortable and convenient location and time for vaccination may ensure better participation.\[[@ref33]\]

Hosting a vaccination program in company {#sec2-19}
----------------------------------------

Hosting a vaccination program within company premises is a great way to demonstrate a company\'s commitment to providing accessible health and wellness benefits. Extending vaccination to employees\' families can be a significant step to ensure better participation \[[Figure 2](#F2){ref-type="fig"}\].\[[@ref33]\]

![Hosting vaccination program in company\[[@ref33]\]](IJOEM-24-3-g002){#F2}

[Tables 8](#T8){ref-type="table"} provide a summary of recommendations by IAOH for working adults

###### 

Vaccination recommended by IAOH for working adults

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Vaccine                                       19-21 years                                                                                                        22-26 years
  --------------------------------------------- ------------------------------------------------------------------------------------------------------------------ -------------
  Influenza vaccine (quadrivalent)              1 dose annually                                                                                                    

  Pneumococcal conjugate (PCV13)                Special situationS                                                                                                 1 dose\*

  Pneumococcal polysaccharide (PPSV23)          1 dose                                                                                                             

  Tetanus, diphtheria, pertussis (Tdap or Td)   1 dose Tdap, then Td booster every 10 years                                                                        

  Measles, mumps, rubella (MMR)                 2 doses (4-8 weeks interval)\                                                                                      
                                                1 dose (if previously immunized)                                                                                   

  Varicella                                     2 doses (4-8 weeks interval)^δ^\                                                                                   
                                                1 dose (if previously received)^δ^                                                                                 

  Zoster live                                                                                                                                                      1 dose

  Human papillomavirus (HPV)                    3 doses schedule (0, 1-2 months, 6 months)^∞^                                                                      

  Hepatitis A (Hep A)                           2 doses (Single-antigen vaccine; 0 and 6-12 months) or 3 doses (Combined Hep A and Hep B; 0, 1, and 6 months)^@^   

  Hepatitis B (Hep B)                           3 doses (0, 1, 6 months)^!^                                                                                        

  Meningococcal A, C, W, Y                      1 or 2 doses depending on indication, then booster every 5 years if risk remains                                   

  Haemophilus influenzae type b (Hib)           1 or 3 doses depending on indication                                                                               

  Special vaccine recommendation                                                                                                                                   

  Rabies^\$^                                    Total 3-4 doses\                                                                                                   
                                                Pre-exposure: 4 doses (0, 7, 21, 28 days)\                                                                         
                                                Post-exposure: 4 doses (0, 3, 7, 14/28 days)                                                                       

  Typhoid                                       Compulsory for food-handlers                                                                                       
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of past infection. No recommendation Recommended vaccination for adults with an additional risk factor. SPCV13 is recommended in series with PPSV23 for adults aged ≥19 years with an immunocompromising condition, CSF leak, or cochlear implant. For PPSV23 dosing instruction, please refer to the respective guideline for special situations. \*Administer 1 dose PCV13 followed by 1 dose PPSV23 at least 1 year after PCV13. PCV13 is recommended based on shared clinical decision making for adults who do not have an immunocompromising condition, cerebrospinal fluid (CSF) leak, or cochlear implant, and who have not previously received PCV13. Immunocompromising conditions include chronic renal failure, nephrotic syndrome, immunodeficiency, iatrogenic immunosuppression, generalized malignancy, human immunodeficiency virus, Hodgkin disease, leukemia, lymphoma, multiple myeloma, solid organ transplants, congenital or acquired asplenia, sickle cell disease, or other hemoglobinopathies. ^δ^2-dose series VAR 4--8 weeks apart if previously did not receive the varicella-containing vaccine (VAR or MMRV \[measles mumps-rubella-varicella vaccine\] for children); if previously received 1 dose varicella-containing vaccine: 1 dose VAR at least 4 weeks after first dose. ^∞^A three-dose schedule (at 0, 1--2 months, and 6 months) is recommended for individuals above 15 to 45 years. ^@^Not at risk but want protection from hepatitis A: Single-antigen vaccine formulations: Administer in a 2-dose schedule at 0 and 6--12 months. Combined hepatitis A and hepatitis B vaccine: Administer 3 doses at 0, 1, and 6 months. ^!^Not at risk but want protection from hepatitis B: 3 doses. The second dose. should be administered one month after the first dose; the third dose should be administered at least 6 months after the first dose ^\$^Pre-exposure prophylaxis, as well as post-exposure vaccine, is recommended for risk groups such as medical and paramedical personnel treating rabies patients, veterinarians, laboratory personnel working with rabies virus; others, such as zookeepers, dog catchers, forest staff; postmen, policemen, courier boys, etc.

  --------------------------------------------------------------------------------------------------------------------------------------
  Vaccine recommendation for healthcare workers    
  ------------------------------------------------ -------------------------------------------------------------------------------------
  Recommended vaccines                             Hepatitis A and B\
                                                   Tdap\
                                                   Varicella (Chickenpox)\
                                                   Polio (IPV)\
                                                   Influenza\
                                                   Pneumococcal\
                                                   Typhoid\
                                                   MMR\
                                                   Meningococcal (ACWY)\
                                                   Rabies

  Vaccination during preconception and pregnancy   

  Preconception                                    Hepatitis B\
                                                   Varicella (Chickenpox)\
                                                   MMR\
                                                   HPV\
                                                   Influenza

  During pregnancy                                 TT/Td\
                                                   Tdap\
                                                   Influenza\^

  Lactation                                        All vaccines except typhoid and yellow fever can be given as catch-up immunization.

  Vaccines recommended for mass gathering          

  Kumbh Mela attendees                             Typhoid---Strong recommendation\
                                                   Influenza---Strong recommendation\
                                                   Hepatitis A---Strong recommendation\
                                                   Hepatitis B---For prolonged stay\
                                                   Japanese encephalitis---If stay is over 1 month\
                                                   Yellow fever---For endemic countries\
                                                   Rabies---Pre-exposurePolio---1 boosterCholera oral vaccine advised

  Hajj pilgrims                                    Meningococcal (mandatory)---Mandatory\
                                                   Influenza---Recommended\
                                                   Polio (IPV)---\<15 years, endemic countries\
                                                   Yellow fever---Endemic countries\
                                                   Pneumococcal\
                                                    PCV13: 4 weeks before traveling for Hajj\
                                                    PPSV23: Post-return from Hajj (depends upon risk status)\
                                                   Hepatitis A and B---Recommended
  --------------------------------------------------------------------------------------------------------------------------------------

\^At any stage of pregnancy. Note: No QIV in India has labeled indication for pregnancy.ªStrong recommendation. Meningococcal ACWY special situations:

Anatomical or functional asplenia (including sickle cell disease), HIV infection, persistent complement component deficiency, eculizumab use: 2-dose series MenACWY (Menactra, Menveo) at least 8 weeks apart and revaccinate every 5 years if risk remains.

Travel in countries with hyperendemic or epidemic meningococcal disease, microbiologists routinely exposed to *Neisseria meningitidis*: 1 dose MenACWY and revaccinate every 5 years if risk remains.

First-year college students who live in residential housing (if not previously vaccinated at age 16 years or older) and military recruits: 1 dose MenACWY.

Hepatitis A special situations:

At risk for HAV infection (2-dose series Hep A or 3-dose series Hep A-Hep B; as mentioned above.)

Chronic liver disease

Clotting factor disorders

Men who have sex with men

Injection or non-injection drug use

Homelessness

Work with HAV in research laboratory or nonhuman primates with HAV infection

Travel in countries with high or intermediate endemic hepatitis AClose personal contact with international adoptee

Hepatitis B special situations:

At risk for HBV infection (3-dose series, as mentioned above)

Hepatitis C virus infection

Chronic liver diseaseSexual exposure risk

HIV infection

Current or recent injection drug use

Percutaneous or mucosal risk for exposure to blood

Incarcerated persons

Travel in countries with high or intermediate endemic hepatitis B

*Haemophilus influenzae* type b vaccination special situations:

Anatomical or functional asplenia (including sickle cell disease): 1 dose Hib if previously did not receive Hib; if elective splenectomy, 1 dose Hib, preferably at least 14 days before splenectomy

Hematopoietic stem cell transplant (HSCT): 3-dose series Hib 4 weeks apart starting 6--12 months after successful transplant, regardless of Hib vaccination history

IPV: inactivated polio vaccine, Tdap: tetanus diphtheria (acellular) pertussis; TT: tetanus toxoid; Td: tetanus and adult diphtheria; HPV: human papillomavirus; MMR: measles, mumps, and rubella

C[ONCLUSION AND]{.smallcaps} F[UTURE]{.smallcaps} D[IRECTIVES]{.smallcaps} {#sec1-5}
==========================================================================

VPDs cause a substantial health care burden in India and should be effectively controlled with vaccination, especially in the workplace. Apart from the direct benefits of vaccination such as productivity and reduction in absenteeism, it is important to highlight the spin-off benefits of vaccination in terms of reduction in cardiovascular comorbidities and hospitalization. Adult vaccination potentially enhances company/business profits. Awareness must be created about vaccination and vaccine recommendations must be circulated among all working professionals in any industry. Extending the benefits of adult vaccination to the family members of employees is pertinent for ensuring wider protection; thus, the risk of contagion can be further reduced. This will keep the family safe and healthy and reduce the rate of absenteeism.
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